搜索
Search
img

News Center

新闻中心

Kintor Pharmaceutical Signs Strategic Cooperation Agreement with MabPlex

  • Time of issue:2020-09-30

(Summary description)On 30 September 2020, Kintor Pharmaceutical Limited announced that Kintor Pharmaceutical entered into a strategic cooperation agreement with MabPlex International Ltd. , pursuant to which both parties will carry out all-round cooperation on the research and development and production in biological macromolecular drugs.

Kintor Pharmaceutical Signs Strategic Cooperation Agreement with MabPlex

(Summary description)On 30 September 2020, Kintor Pharmaceutical Limited announced that Kintor Pharmaceutical entered into a strategic cooperation agreement with MabPlex International Ltd. , pursuant to which both parties will carry out all-round cooperation on the research and development and production in biological macromolecular drugs.

  • Categories:Company news
  • Author:
  • Origin:
  • Time of issue:2020-09-30 15:40
  • Views:
Information

On 30 September 2020, Kintor Pharmaceutical Limited (Stock code: 9939.HK, hereinafter referred to as “Kintor Pharmaceutical”) announced that Kintor Pharmaceutical entered into a strategic cooperation agreement with MabPlex International Ltd. (hereinafter referred to as “MabPlex”), pursuant to which both parties will carry out all-round cooperation on the research and development and production in biological macromolecular drugs, and the CMC work for GT90008 (PD-L1/TGF-β BsAb), the first project to be co-operated by both parties will be officially initiated. Through this strong cooperation, the research and development progress of Kintor Pharmaceutical in the field of biological macromolecular drugs will be accelerated to provide more and better solutions for patients around the world.

 

Dr. Tong Youzhi, the Founder, Chairman and Chief Executive Officer of Kintor Pharmaceutical, said, “Kintor Pharmaceutical is actively expanding the strategic layout in the biopharmaceutical industry. The GT90008 project appears to be the first BsAb project of our Company, and therefore, we attach great importance to the choice of CDMO partners. We believe that MabPlex’s capability in ‘One Stop’ CDMO service will promote the research and development progress of GT90008 project with high quality.”

 

Dr. Fang Jianmin, Chairman of MabPlex, said, “It is a great honor to provide efficient and compliant services in the process of Kintor Pharmaceutical’s expansion in biopharmaceutical industry. We are capable and confident to advance the GT90008 project efficiently, and help Kintor Pharmaceutical complete the clinical application of this project in both China and the United States.”

 

About Kintor Pharmaceutical Limited

 

Founded in 2009, Kintor Pharmaceuticals concentrates on the R&D and industrialization of “best-in-class” and “first-in-class” innovative drugs, and strives to become a leading enterprise in the R&D and commercialization of innovative therapies. The Company was founded by national-level talents, after years of development, centered upon androgen receptor (AR) related diseases and researched and developed product portfolios in multiple channels covering cancers with a globally high incidence and illnesses yet to meet their clinical requirements, such as prostate cancer, breast cancer, liver cancer and hair loss. Kintor Pharmaceuticals has prospectively deployed a diversified product pipeline that includes small molecule innovative drugs, bio-innovative drugs and combination therapies, including 5 products that are undergoing clinically researched androgen receptor antagonists, ALK-1 monoclonal antibody, mTOR kinase inhibitors and Hedgehog inhibitors, as well as PD-L1/TGF-β dual-targeting antibody, AR-Degrader and c-Myc inhibitors that are undergoing preclinical research. Globally, the Company has more than 60 patents obtained or under review, many of which are listed as the “Major New Drugs Discovery” in National 12th and 13th Five-Year Plans. On 22 May 2020, the Company was officially listed on the Hong Kong Stock Exchange with the stock code 9939.HK. Visit http://www.kintor.com.cn for more information.

 

About MabPlex

 

The large-scale culture of CHO cells and ADC technology platform possessed by MabPlex can provide customers with one-stop and customized service for the whole process from cell line construction, process development to clinical sample production and even commercial production of innovative biopharmaceutical drugs such as mAb, BsAb, fusion protein, ADC and biosimilar. It is one of the few CDMO companies in the world that is capable to provide full-process services from research and development to commercial production of ADC drugs. MabPlex has cooperated with dozens of customers from China, the United States and Europe to undertake 48 comprehensive projects, 18 of which have been approved for clinical trials by the FDA, NMPA and TGA. Five customers have conducted Phase II clinical trials in the United States using the clinical samples provided by MabPlex. Visit http://www.mabplex.com for more information.

Scan the QR code to read on your phone